Enhancement of binding of the dihydropyridine calcium antagonist PN200-110 to human myometrial sarcolemma by the heterologous calcium antagonist diltiazem.
Binding of the dihydropyridine calcium antagonist PN200-110 was studied in human myometrial membranes. PN200-110 bound reversibly and with high affinity to membrane fragments. The highest concentration of binding sites was found in the sarcolemma. The benzothiazepine calcium antagonist diltiazem stimulated PN200-110 binding by increasing the amount bound at equilibrium. Kinetic studies detected a fast and slow rate of dissociation in the presence of diltiazem.
D002121:Calcium Channel Blockers / Q000378:metabolism*; D002458:Cell Fractionation; D004110:Diltiazem / Q000494:pharmacology*; D005260:Female; D006801:Humans; D017275:Isradipine; D007700:Kinetics; D009215:Myometrium / Q000378:metabolism*; D010069:Oxadiazoles / Q000378:metabolism*; D012508:Sarcolemma / Q000378:metabolism*; D013347:Subcellular Fractions / Q000378:metabolism
D002121:Calcium Channel Blockers; D010069:Oxadiazoles; D004110:Diltiazem; D017275:Isradipine